Since the establishment of Koa Shoji in 1991, the Japanese generics market has been experiencing drastic changes. In the 1990s, the share of generics was lower than it is now. In the 2000s, the Japanese government started to encourage the use of generics to save social insurance costs. By 2005, the share of generics grew over 30%. And by 2013, it had got over 40%. Finally in 2015, the government decided to give further support to make it grow over 80% by 2020. In 2018, it has grown to over 70%. Now we are going to achieve the goal.

Koa Shoji has never been left behind by this movement. We’ve been surviving in severe competition and leading the Japanese generics business with our sufficient experience, tight relationship with our suppliers and customers, and updating our knowledge and facilities. Our 30-year experience proves the strength of our sales force.

Importing and selling APIs are just part of, but not all of our business.

As you may read the details in “Our Business”, our “import of APIs” starts in a long term. We begin our business with investigating which APIs will be necessary in Japan in the future.

And we continue various research and investigation:
Which foreign API manufacturer can satisfy the Japanese standards?
What should we do to make the quality of their APIs meet the Japanese standards?
What is necessary to achieve “stable supply of safe and reliable APIs at reasonable prices”?
What kind of follow-up is needed after the import and sale of APIs?
Taking all of the above conditions into consideration, we proceed with our business.

It brings us the necessity of providing various kinds of services.
To carry our sales activities smoothly, we organize ourselves and equip with facilities to provide them.